Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
100 results
  • IFN-γ for Friedreich ataxia: present evidence. [Journal Article]
  • NDNeurodegener Dis Manag 2015; 5(6):497-504
  • Wells M, Seyer L, … Lynch DR
  • IFN-γ-1b is currently US FDA approved as an orphan drug for the treatment of chronic granulomatous disease and severe malignant osteopetrosis. It is administered via subcutaneous injection and is a p...
  • Inhaled Interferon and Diffusion Capacity in Idiopathic Pulmonary Fibrosis (IPF). [Randomized Controlled Trial]
  • SVSarcoidosis Vasc Diffuse Lung Dis 2015; 32(1):37-42
  • Skaria SD, Yang J, … Smaldone GC
  • CONCLUSIONS: DLCO was significantly improved following inhaled (IFN-γ) as treatment for IPF. Our data suggest that previous studies utilizing parenteral IFN-γ may have failed because of the mode of delivery. Future randomized, controlled, phase 3 trials, comparing the difference in PFT behavior (specifically DLCO) longitudinally may be more sensitive to drug effect and serve as a valuable clinical endpoint.
New Search Next